Challenges in Tuberculosis Vaccine Development

Exam-Focused Notes on Tuberculosis Vaccine Research

Disease Overview

• Tuberculosis (TB) is the deadliest infectious disease, outpacing COVID-19 at its peak.
• TB can present as Pulmonary TB (PTB) (infectious) or Extrapulmonary TB (EPTB) (harder to diagnose, more debilitating, and sometimes fatal).
• In low- and middle-income countries, TB incidence ranges between 200 to 300 per 100,000 population. Eliminating TB requires reducing this to 10-20 per 100,000.

India's TB Burden

• India has one of the highest TB burdens globally.
• Policy for TB elimination involves a holistic approach including better detection, preventive therapy, and vaccination.
• There's currently no structured TB vaccination strategy for school-age children in India.

Recent Research Findings

• The PreVenTB trial, conducted by the Indian Council of Medical Research (ICMR), involved over 12,700 contacts of TB patients across 18 sites in India.
• Vaccines tested:
  • VPM1002 and Immuvac.

Efficacy Results

• VPM1002 efficacy:

  • 50.4% against EPTB.
  • 64.6% efficacy in children aged 6-14 against all forms of TB.
  • Overall 21.4% efficacy against all TB.

• Immuvac efficacy:

  • Over 60% efficacy against EPTB in children aged 6-10.
  • More than 60% efficacy against disease progression in latent infection cases.

Nutritional Considerations

• Lower vaccine efficacy linked to individuals with low Body Mass Index (BMI), emphasizing the need for nutritional support in TB care.

Operational Advantages of VPM1002

• Single-dose vaccine based on a modified BCG platform, facilitating easier logistics and scalability for mass production.

Historical Context & Policy Actions

• Previous public health innovations, such as the TrueNat molecular test and Bharat Biotech’s Covaxin, underscore the need for a proactive approach rather than waiting for ideal solutions.
• Historical approval of vaccines despite modest efficacy shows a willingness to act on urgent health threats.

Integration into Health Programs

• Vaccination research needs to be integrated with:
  • Early detection strategies.
  • Preventive treatment for latent TB.
  • Nutritional support programs.

Strategic Implications

• TB control strategies must be multifaceted, combining early detection, targeted vaccinations for PTB and EPTB, and nutritional supplementation.
• The aim is to quickly deploy available vaccines while awaiting more advanced options.

Conclusion

• Immediate actionable solutions, supported by robust research evidence, are essential in combating TB.
• Waiting indefinitely for perfect vaccines could jeopardize progress, highlighting the importance of pragmatism in public health responses.